NASDAQ:ARWR Arrowhead Pharmaceuticals (ARWR) Stock Price, News & Analysis $22.22 -1.03 (-4.43%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$21.98▼$23.4450-Day Range$22.22▼$29.5452-Week Range$20.67▼$39.83Volume1.01 million shsAverage Volume1.23 million shsMarket Capitalization$2.76 billionP/E RatioN/ADividend YieldN/APrice Target$44.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Arrowhead Pharmaceuticals alerts: Email Address Arrowhead Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside99.1% Upside$44.25 Price TargetShort InterestBearish8.41% of Shares Sold ShortDividend StrengthN/ASustainability-2.55Upright™ Environmental ScoreNews Sentiment0.56Based on 23 Articles This WeekInsider TradingSelling Shares$237,480 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.02) to ($3.72) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.37 out of 5 starsMedical Sector273rd out of 910 stocksPharmaceutical Preparations Industry117th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingArrowhead Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageArrowhead Pharmaceuticals has only been the subject of 4 research reports in the past 90 days.Read more about Arrowhead Pharmaceuticals' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted8.41% of the outstanding shares of Arrowhead Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverArrowhead Pharmaceuticals has a short interest ratio ("days to cover") of 10, which indicates bearish sentiment.Change versus previous monthShort interest in Arrowhead Pharmaceuticals has recently increased by 4.29%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldArrowhead Pharmaceuticals does not currently pay a dividend.Dividend GrowthArrowhead Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArrowhead Pharmaceuticals has received a 39.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Cardiovascular siRNA medication", "RNA interference medication for cancer", and "Liver-disease medication (A05)" products. See details.Environmental SustainabilityThe Environmental Impact score for Arrowhead Pharmaceuticals is -2.55. Previous Next 2.5 News and Social Media Coverage News SentimentArrowhead Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Arrowhead Pharmaceuticals this week, compared to 5 articles on an average week.Search InterestOnly 3 people have searched for ARWR on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows3 people have added Arrowhead Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arrowhead Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $237,480.00 in company stock.Percentage Held by InsidersOnly 4.50% of the stock of Arrowhead Pharmaceuticals is held by insiders.Percentage Held by Institutions62.61% of the stock of Arrowhead Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Arrowhead Pharmaceuticals' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($4.02) to ($3.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arrowhead Pharmaceuticals is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arrowhead Pharmaceuticals is -5.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArrowhead Pharmaceuticals has a P/B Ratio of 8.14. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Arrowhead Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…Go here now to watch my new documentary About Arrowhead Pharmaceuticals Stock (NASDAQ:ARWR)Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Read More ARWR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARWR Stock News HeadlinesSeptember 7 at 1:31 AM | americanbankingnews.comBrokers Issue Forecasts for Arrowhead Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:ARWR)September 6 at 3:06 AM | americanbankingnews.comAnalysts Offer Predictions for Arrowhead Pharmaceuticals, Inc.'s FY2025 Earnings (NASDAQ:ARWR)September 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.September 5 at 4:48 PM | markets.businessinsider.comArrowhead Pharmaceuticals (ARWR) Receives a Buy from TD CowenSeptember 4 at 11:19 AM | markets.businessinsider.comArrowhead’s Plozasiran Shows Promise Amidst Competition and Operational Concerns: Maintaining Hold RatingSeptember 4 at 6:19 AM | markets.businessinsider.comStrong Buy Rating for Arrowhead Pharmaceuticals’ Plozasiran Based on Positive Clinical Trial Outcomes and Market PotentialSeptember 4 at 2:45 AM | americanbankingnews.comArrowhead Pharmaceuticals' (ARWR) Buy Rating Reaffirmed at HC WainwrightSeptember 3, 2024 | marketwatch.comArrowhead Pharmaceuticals Shares Climb on Plans to File New Drug Application for PlozasiranSeptember 7, 2024 | Porter & Company (Ad)Trump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. Hopelessness abounds. And looking in, the future here looks bleak for these forgotten souls. But in a strange twist of fate, something miraculous is taking place…September 3, 2024 | markets.businessinsider.comWhy Arrowhead Pharmaceuticals Is Rising In Pre-market?September 3, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals’ Plozasiran: A Promising Treatment for FCS with Strong Market PotentialSeptember 3, 2024 | investopedia.comArrowhead Pharmaceuticals Stock Climbs on Plans To Seek FDA Approval for New DrugSeptember 3, 2024 | businesswire.comArrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia SyndromeSeptember 3, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals: Strong Buy Rating on Robust Clinical Data and Promising Commercial ProspectsAugust 22, 2024 | msn.comARWR: Two Obesity Assets to Enter the Clinic in 2025…August 16, 2024 | markets.businessinsider.comArrowhead Pharmaceuticals: A Cautious Hold Amid Promising Obesity Treatments and Competitive MarketAugust 15, 2024 | finance.yahoo.comArrowhead announces push into obesity space with two gene therapiesAugust 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK), Arrowhead Pharmaceuticals (ARWR) and Syndax Pharmaceuticals (SNDX)See More Headlines Receive ARWR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arrowhead Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/07/2024Fiscal Year End9/30/2024Next Earnings (Estimated)12/04/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ARWR CUSIPN/A CIK879407 Webwww.arrowheadpharma.com Phone(626) 304-3400Fax626-304-3401Employees400Year FoundedN/APrice Target and Rating Average Stock Price Target$44.25 High Stock Price Target$60.00 Low Stock Price Target$27.00 Potential Upside/Downside+99.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($4.25) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-205,270,000.00 Net Margins-163.32% Pretax Margin-2,792.41% Return on Equity-152.95% Return on Assets-63.93% Debt Debt-to-Equity RatioN/A Current Ratio4.65 Quick Ratio4.65 Sales & Book Value Annual Sales$19.65 million Price / Sales140.46 Cash FlowN/A Price / Cash FlowN/A Book Value$2.73 per share Price / Book8.14Miscellaneous Outstanding Shares124,200,000Free Float118,611,000Market Cap$2.76 billion OptionableOptionable Beta0.96 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesDr. Christopher R. Anzalone Ph.D. (Age 55)CEO, President & Director Comp: $1.6MMr. Kenneth A. Myszkowski (Age 58)Chief Financial Officer Comp: $834.34kMr. Patrick O'Brien J.D. (Age 60)PharmD, COO, General Counsel & Secretary Comp: $835.14kDr. James C. Hamilton M.D. (Age 46)MBA, Chief of Discovery & Translational Medicine Comp: $762.14kDr. Mark M. Davis Ph.D.Founder and Founder & Director of Insert Therapeutics Inc & CalandoDr. Vincent Anzalone CFAHead of Investor Relations & VPMr. Howard LovyDirector of CommunicationsDr. Bruce D. Given M.D. (Age 70)Chief Medical Scientist Comp: $486.31kDr. Mark Seefeld (Age 70)Head of Toxicology & VP Ms. Tracie Oliver (Age 62)Chief Commercial Officer Comp: $449.58kMore ExecutivesKey CompetitorsBausch Health CompaniesNYSE:BHCAmicus TherapeuticsNASDAQ:FOLDPerrigoNYSE:PRGOJazz PharmaceuticalsNASDAQ:JAZZIonis PharmaceuticalsNASDAQ:IONSView All CompetitorsInsiders & InstitutionsAlgert Global LLCBought 20,656 shares on 8/16/2024Ownership: 0.033%Creative PlanningBought 2,420 shares on 8/16/2024Ownership: 0.023%Quarry LPBought 3,000 shares on 8/16/2024Ownership: 0.007%The Manufacturers Life Insurance Company Bought 1,677 shares on 8/15/2024Ownership: 0.120%Scientech Research LLCSold 7,388 shares on 8/15/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions ARWR Stock Analysis - Frequently Asked Questions How have ARWR shares performed this year? Arrowhead Pharmaceuticals' stock was trading at $30.60 at the beginning of 2024. Since then, ARWR stock has decreased by 27.4% and is now trading at $22.22. View the best growth stocks for 2024 here. How were Arrowhead Pharmaceuticals' earnings last quarter? Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) released its quarterly earnings results on Thursday, August, 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.58) by $0.80. The firm's quarterly revenue was down 100.0% on a year-over-year basis. Who are Arrowhead Pharmaceuticals' major shareholders? Arrowhead Pharmaceuticals' top institutional investors include Avoro Capital Advisors LLC (7.16%), Bank of New York Mellon Corp (0.87%), Millennium Management LLC (0.43%) and Principal Financial Group Inc. (0.34%). Insiders that own company stock include Christopher Richard Anzalone, Patrick O'brien, Kenneth Allen Myszkowski, James C Hamilton, Martin Javier San, Douglas B Given, Tracie Oliver, Hongbo Lu, Victoria Vakiener, William D Waddill and Adeoye Y Olukotun. View institutional ownership trends. How do I buy shares of Arrowhead Pharmaceuticals? Shares of ARWR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Arrowhead Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arrowhead Pharmaceuticals investors own include Bellicum Pharmaceuticals (BLCM), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Alibaba Group (BABA), Alliance Resource Partners (ARLP) and Bank of America (BAC). This page (NASDAQ:ARWR) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arrowhead Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arrowhead Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
